Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BGF MDI on Cardiac and Lung Function in COPD With Hyperinflation
NCT07073950Phase 4Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of budesonide, glycopyrrolate metered dose inhaler, formoterol in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Nov 2025; status: recruiting.
02
Drugs
budesonideglycopyrrolate metered dose inhalerformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07073950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073950.